Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer.

Simple item page
dc.contributor.authorIbrahim, Ezzeldin Men_US
dc.contributor.authorZeeneldin, Ahmed Aen_US
dc.contributor.authorAl-Gahmi, Aboelkhair Men_US
dc.contributor.authorSallam, Yasser Aen_US
dc.contributor.authorFawzi, Ehab Een_US
dc.contributor.authorBahadur, Yasser Aen_US
dc.date.accessioned2009-05-28T06:39:05Z
dc.date.available2009-05-28T06:39:05Z
dc.date.issued2007-04-17en_US
dc.description.abstractBACKGROUND: Cetuximab-based combination chemotherapy (CBCC) proved safe and effective as second-line strategy for metastatic colorectal cancer (mCRC). This prospective phase-II study was designed to assess the efficacy and safety of CBCC as first-, second- or third-line among Saudi patients with mCRC. MATERIALS AND METHODS: Patients with mCRC were offered CBCC to assess time-to-disease progression (TTP), response rate and duration, overall survival (OS) and safety. RESULTS: Nineteen patients were eligible and their median age was 51 years. Seven patients received CBCC as first-line and 12 as second- or third-line. Responses: 11 (58%) partial responses, 5 (26%) stable disease and 3 (16%) disease progressions. The median response duration was 4.3 months [95% confidence interval (CI): 3.4-5.2 months]. The median TTP was 6.8 months (95% CI: 2-13.9 months) for all 19 patients compared to 9.3 months (95% CI: 3.9-14.6 months) for the seven patients who received CBCC as first-line. The median OS for the entire population was 12.3 months (95% CI could not be determined). On the other hand, while the median OS for those who received CBCC as first-line have not been reached, the median OS for those who received CBCC after failure of other salvage therapies was 12.3 months (95% CI: 3.2-21.4 months). CBCC was generally tolerable. One patient had a severe hypersensitivity reaction and another fatal cardiac arrest. CONCLUSION: CBCC is active with an acceptable safety profile. Until results from phase-III clinical trials are available, using CBCC as first-line is probably justified.en_US
dc.description.affiliationDepartment of Oncology and Hematology, Sections of Medical Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia. ezzibrahim@kfshrc.edu.saen_US
dc.identifier.citationIbrahim EM, Zeeneldin AA, Al-Gahmi AM, Sallam YA, Fawzi EE, Bahadur YA. Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer. Indian Journal of Cancer. 2007 Apr-Jun; 44(2): 56-61en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/50168
dc.language.isoengen_US
dc.source.urihttps://www.indianjcancer.comen_US
dc.subject.meshAdenocarcinoma --drug therapyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAngiogenesis Inhibitors --administration & dosageen_US
dc.subject.meshAntibodies, Monoclonal --administration & dosageen_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols --administration & dosageen_US
dc.subject.meshCamptothecin --administration & dosageen_US
dc.subject.meshColorectal Neoplasms --drug therapyen_US
dc.subject.meshDisease-Free Survivalen_US
dc.subject.meshExanthema --chemically induceden_US
dc.subject.meshFemaleen_US
dc.subject.meshFluorouracil --administration & dosageen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshInfusions, Intravenousen_US
dc.subject.meshLeucovorin --administration & dosageen_US
dc.subject.meshMaleen_US
dc.subject.meshMaximum Tolerated Doseen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Metastasisen_US
dc.subject.meshOrganoplatinum Compounds --administration & dosageen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshReceptor, erbB-2 --antagonists & inhibitorsen_US
dc.subject.meshSaudi Arabiaen_US
dc.subject.meshSurvival Rateen_US
dc.titleSafety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer.en_US
dc.typeClinical Trial, Phase IIen_US
dc.typeJournal Articleen_US
dc.typeResearch Support, Non-U.S. Gov'ten_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Journal of Cancer